News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dainippon Pharmaceutical , Meiji Seika Kaisha, Ltd. Jointly Market New Formulations For Ebastel Antiallergic Agent


10/19/2005 5:09:29 PM

Tokyo (JCNN) - On July 11, Dainippon Pharmaceutical (TSE: 4506) and Meiji Seika Kaisha (TSE: 2202) jointly launched Ebastel OD Tablet 5mg and Ebastel OD Tablet 10mg, new formulations for the antiallergic agent Ebastel. Based on Dainippon Pharmaceutical's proprietary drug formulation technology, the new products are easily disintegrated in the mouth without water.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES